Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators

US9469615B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Christopher W. Boyce · Flemington, US
• Sylvia Degrado · Scotch Plains, US
• Xiao-Tao Chen · New York, US
• Jun Qin · Edison, US
• Robert Mazzola · Stewartsville, US
• Younong Yu · East Brunswick Township, US
• Kevin D. McCormick · Berkeley Heights, US
• Anandan Palani · Bound Brook, US
• Dong Xiao · Hackettstown, US
• Robert G. Aslanian · Rockaway, US
• Jie Wu · Freeport, US
• Ashwin U. Rao · Avenel, US
• Phieng Siliphaivanh · Newton, US
• Joey L. Methot · Westwood, US
• Hongjun Zhang · Waterloo, CA
• Elizabeth H. Kelley · Cambridge, US
• William Colby Brown · Cleveland Heights, US
• Qin Jiang · Latham, US
• Jolicia Polivina Gauuan · Schenectady, US
• Andrew J. Leyhane · Latham, US
• Purakkattle Biju · Piscataway, US
• Pawan Dhondi · Elizabeth, US
• Li Dong · Lawrenceville, US
• Salem Fevrier · Cranford, US
• Xianhai Huang · Hackettstown, US
• Henry M. Vaccaro · South Plainfield, US

Key dates

• Filing date: Dec 19, 2011
• Grant date: Oct 18, 2016
• Expiry date: May 27, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D241/38
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J1, J2, R1, R2, R3, R22, Ra, Rb, Rc, Rd, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.